These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 11113068)

  • 1. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group.
    Fedorak RN; Gangl A; Elson CO; Rutgeerts P; Schreiber S; Wild G; Hanauer SB; Kilian A; Cohard M; LeBeaut A; Feagan B
    Gastroenterology; 2000 Dec; 119(6):1473-82. PubMed ID: 11113068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group.
    Schreiber S; Fedorak RN; Nielsen OH; Wild G; Williams CN; Nikolaus S; Jacyna M; Lashner BA; Gangl A; Rutgeerts P; Isaacs K; van Deventer SJ; Koningsberger JC; Cohard M; LeBeaut A; Hanauer SB
    Gastroenterology; 2000 Dec; 119(6):1461-72. PubMed ID: 11113067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group.
    van Deventer SJ; Elson CO; Fedorak RN
    Gastroenterology; 1997 Aug; 113(2):383-9. PubMed ID: 9247454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease.
    Sands BE; Winston BD; Salzberg B; Safdi M; Barish C; Wruble L; Wilkins R; Shapiro M; Schwertschlag US;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):399-406. PubMed ID: 11876692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease.
    Colombel JF; Rutgeerts P; Malchow H; Jacyna M; Nielsen OH; Rask-Madsen J; Van Deventer S; Ferguson A; Desreumaux P; Forbes A; Geboes K; Melani L; Cohard M
    Gut; 2001 Jul; 49(1):42-6. PubMed ID: 11413109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group.
    Campion GV; Lebsack ME; Lookabaugh J; Gordon G; Catalano M
    Arthritis Rheum; 1996 Jul; 39(7):1092-101. PubMed ID: 8670316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
    Khanna R; Preiss JC; MacDonald JK; Timmer A
    Cochrane Database Syst Rev; 2015 May; (5):CD007572. PubMed ID: 25942580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.
    Herrlinger KR; Witthoeft T; Raedler A; Bokemeyer B; Krummenerl T; Schulzke JD; Boerner N; Kueppers B; Emmrich J; Mescheder A; Schwertschlag U; Shapiro M; Stange EF
    Am J Gastroenterol; 2006 Apr; 101(4):793-7. PubMed ID: 16635225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
    Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
    Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.
    Carreño V; Zeuzem S; Hopf U; Marcellin P; Cooksley WG; Fevery J; Diago M; Reddy R; Peters M; Rittweger K; Rakhit A; Pardo M
    J Hepatol; 2000 Feb; 32(2):317-24. PubMed ID: 10707873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
    Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
    J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease.
    Schreiber S; Siegel CA; Friedenberg KA; Younes ZH; Seidler U; Bhandari BR; Wang K; Wendt E; McKevitt M; Zhao S; Sundy JS; Lee SD; Loftus EV
    J Crohns Colitis; 2018 Aug; 12(9):1014-1020. PubMed ID: 29846530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma.
    Tilg H; van Montfrans C; van den Ende A; Kaser A; van Deventer SJ; Schreiber S; Gregor M; Ludwiczek O; Rutgeerts P; Gasche C; Koningsberger JC; Abreu L; Kuhn I; Cohard M; LeBeaut A; Grint P; Weiss G
    Gut; 2002 Feb; 50(2):191-5. PubMed ID: 11788558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ; Fuss IJ; Mayer L; Elson CO; Sandborn WJ; Present D; Dolin B; Goodman N; Groden C; Hornung RL; Quezado M; Yang Z; Neurath MF; Salfeld J; Veldman GM; Schwertschlag U; Strober W;
    N Engl J Med; 2004 Nov; 351(20):2069-79. PubMed ID: 15537905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection.
    McHutchison JG; Giannelli G; Nyberg L; Blatt LM; Waite K; Mischkot P; Pianko S; Conrad A; Grint P
    J Interferon Cytokine Res; 1999 Nov; 19(11):1265-70. PubMed ID: 10574619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of IL-10 for induction of anemia during inflammation.
    Tilg H; Ulmer H; Kaser A; Weiss G
    J Immunol; 2002 Aug; 169(4):2204-9. PubMed ID: 12165551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.